Adverse events occurring in ≥ 10% of the patients
| Event . | All grades, n (%) . | Grade 3 and 4, n (%) . | ||||
|---|---|---|---|---|---|---|
| MP (n = 424) . | CTDa (n = 427) . | P* . | MP (n = 424) . | CTDa (n = 427) . | P* . | |
| Cytopenia† | 84 (19.8) | 66 (15.5) | .11 | 64 (15.1) | 47 (11.0) | .084 |
| Thromboembolic events‡ | 20 (4.7) | 68 (15.9) | < .0001 | |||
| Sensory neuropathy | 25 (5.9) | 101 (23.7) | < .0001 | 2 (0.5) | 11 (2.6) | .021 |
| Motor neuropathy | 11 (2.6) | 50 (11.7) | < .0001 | 5 (1.2) | 17 (4.0) | .016 |
| Constipation | 76 (17.9) | 175 (41.0) | < .0001 | 5 (1.2) | 15 (3.5) | .039 |
| Infection | 111 (26.2) | 137 (32.1) | .060 | 31 (7.3) | 55 (12.9) | .0086 |
| Rash | 30 (7.1) | 65 (15.2) | .00019 | 3 (0.7) | 7 (1.6) | .34 |
| Elevated AP level‡ | 40 (9.4) | 66 (15.5) | .0093 | |||
| Event . | All grades, n (%) . | Grade 3 and 4, n (%) . | ||||
|---|---|---|---|---|---|---|
| MP (n = 424) . | CTDa (n = 427) . | P* . | MP (n = 424) . | CTDa (n = 427) . | P* . | |
| Cytopenia† | 84 (19.8) | 66 (15.5) | .11 | 64 (15.1) | 47 (11.0) | .084 |
| Thromboembolic events‡ | 20 (4.7) | 68 (15.9) | < .0001 | |||
| Sensory neuropathy | 25 (5.9) | 101 (23.7) | < .0001 | 2 (0.5) | 11 (2.6) | .021 |
| Motor neuropathy | 11 (2.6) | 50 (11.7) | < .0001 | 5 (1.2) | 17 (4.0) | .016 |
| Constipation | 76 (17.9) | 175 (41.0) | < .0001 | 5 (1.2) | 15 (3.5) | .039 |
| Infection | 111 (26.2) | 137 (32.1) | .060 | 31 (7.3) | 55 (12.9) | .0086 |
| Rash | 30 (7.1) | 65 (15.2) | .00019 | 3 (0.7) | 7 (1.6) | .34 |
| Elevated AP level‡ | 40 (9.4) | 66 (15.5) | .0093 | |||